Compare · BAX vs VVOS
BAX vs VVOS
Side-by-side comparison of Baxter International Inc. (BAX) and Vivos Therapeutics Inc. (VVOS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BAX and VVOS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BAX is the larger of the two at $42.70B, about 745.3x VVOS ($57.3M).
- Over the past year, BAX is down 40.5% and VVOS is down 69.0% - BAX leads by 28.5 points.
- VVOS has been more active in the news (7 items in the past 4 weeks vs 5 for BAX).
- BAX has more recent analyst coverage (25 ratings vs 1 for VVOS).
- Company
- Baxter International Inc.
- Vivos Therapeutics Inc.
- Price
- $18.15-1.44%
- $0.83-4.46%
- Market cap
- $42.70B
- $57.3M
- 1M return
- +5.95%
- -25.78%
- 1Y return
- -40.53%
- -69.04%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 5
- 7
- Recent ratings
- 25
- 1
Baxter International Inc.
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.
Vivos Therapeutics Inc.
Vivos Therapeutics, Inc., a medical technology company, engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing, such as mild-to-moderate obstructive sleep apnea (OSA). Its treatment, the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of mild to moderate OSA. Vivos Therapeutics also offers VivoScore, a comprehensive home sleep apnea test. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
Latest BAX
- Baxter Showcases Recent Innovations at AORN Global Surgical Conference & Expo 2026
- SEC Form 3 filed by new insider Foster Julie
- SEC Form 3 filed by new insider Wallace Steven P.
- SEC Form 3 filed by new insider Teaff James
- Baxter to Host First-Quarter 2026 Financial Results Conference Call for Investors
- Baxter Introduces the IV Verify Line Labeling System, an Automated Solution to Improve IV Labeling in Healthcare Settings
- Baxter to Host Annual Meeting of Stockholders in Virtual Format
- Pet Partners and the Baxter Foundation Expand Therapy Animal Programs to Support 100,000 Patients and Healthcare Workers in Two-Year Pilot
- SEC Form DEFA14A filed by Baxter International Inc.
- SEC Form DEF 14A filed by Baxter International Inc.
Latest VVOS
- Vivos Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Vivos Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-K filed by Vivos Therapeutics Inc.
- Vivos Therapeutics Reports Full Year 2025 Financial Results
- Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call
- SEC Form 3 filed by new insider V-Co Investors 3 Llc
- Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners
- Vivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- SEC Form 4 filed by Skaff Michael C
- SEC Form NT 10-K filed by Vivos Therapeutics Inc.